Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

Running, not enrolling · Not applicable

Conditions studied: Huntington Disease, Parkinson Disease

In brief

The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.

Key facts

Study ID

NCT07213648

Run by

University of Virginia

People needed

136

Starts

2025-11-20

Expected to finish

2026-09-01

Last updated by the study team

2026-07-20

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable)
• With anxiety symptoms (NeuroQoL Anxiety ≥12)

You may not qualify if…

• Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min/telephone ≤11)
• Unable to read and understand English
• Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later)
• Not located in the USA
• <21 years old
• Active suicidality based on the answer "yes" to questions 4, 5, or 6b of the Columbia-Suicide Severity Rating Scale (Screen version)

Where it is running

• Univeristy of Virginia School of Nursing — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.